SCHEDULE: T. Rowe Price Investment Management Discloses 10.8% Stake in Hologic Inc.

T. Rowe Price Investment Management, Inc. has disclosed a significant beneficial ownership stake of 10.8% in Hologic Inc., totaling over 24 million shares of common stock.

Summary

• T. Rowe Price Investment Management, Inc. reported beneficial ownership of 24,083,297 shares of Hologic Inc. common stock.
• This ownership represents 10.8% of Hologic Inc.'s outstanding common stock.
• The reporting person, an investment adviser, holds sole voting power over 23,700,485 shares and sole dispositive power over 24,083,297 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Hologic Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant 10.8% beneficial ownership by a reputable investment management firm like T. Rowe Price in Hologic Inc. is generally viewed as a positive indicator of institutional confidence in the company's long-term prospects, even though the filing itself is a factual disclosure.

Positives

• A major institutional investor, T. Rowe Price Investment Management, Inc., holds a significant 10.8% stake in Hologic Inc., indicating confidence in the company.
• The investment is stated to be for ordinary course of business, not for control, suggesting a passive, long-term investment perspective.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, mitigating immediate governance risks from this specific stake.

Future Outlook

NA

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates continued institutional interest in the medical technology sector, where Hologic Inc. operates. Large stakes by reputable investment firms like T. Rowe Price can signal perceived value or long-term growth potential within the industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by T. Rowe Price may instill confidence among existing and potential shareholders, potentially influencing stock valuation positively.

Key Dates

Keywords

Hologic Inc., T. Rowe Price Investment Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Investment Adviser, Equity Stake, Medical Technology